Immuneering Corporation (NASDAQ:IMRX) CEO Buys $24,762.95 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) CEO Benjamin J. Zeskind purchased 7,015 shares of Immuneering stock in a transaction dated Wednesday, July 2nd. The stock was bought at an average cost of $3.53 per share, with a total value of $24,762.95. Following the completion of the transaction, the chief executive officer owned 2,312,852 shares in the company, valued at approximately $8,164,367.56. This represents a 0.30% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Immuneering Stock Down 5.6%

Shares of Immuneering stock traded down $0.20 during mid-day trading on Friday, reaching $3.39. 908,546 shares of the stock traded hands, compared to its average volume of 2,557,943. The business has a 50-day moving average of $2.00 and a 200 day moving average of $1.84. Immuneering Corporation has a fifty-two week low of $1.00 and a fifty-two week high of $3.87. The stock has a market capitalization of $122.01 million, a PE ratio of -1.73 and a beta of 0.38.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). On average, equities research analysts expect that Immuneering Corporation will post -1.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IMRX has been the topic of several recent analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of Immuneering in a research note on Wednesday, June 18th. Oppenheimer reduced their price target on Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, Mizuho upped their price target on Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $13.25.

Institutional Investors Weigh In On Immuneering

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tang Capital Management LLC acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $27,000. Jane Street Group LLC acquired a new stake in shares of Immuneering in the first quarter valued at approximately $32,000. Marshall Wace LLP acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $47,000. First Manhattan CO. LLC. acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $71,000. Finally, XTX Topco Ltd grew its position in Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after acquiring an additional 20,871 shares during the period. Institutional investors and hedge funds own 67.65% of the company's stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.